MedTrace Logo

Sensitivity of PDL-1-analysis From Pleural Effusion in Non-small Cell Lung Cancer

NCT02855281 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 50

Last updated 2021-03-05

Study results available
· View outcomes & findings →

Summary

This is a prospective diagnostic pilot study to create hypotheses regarding immunocytochemistry (ICC) PD-L1 analysis of pleural effusions in NSCLC patients as compared to the reference standard of PD-L1 immunohistochemistry (IHC). This comparison will be done to assess sensitivity and specificity of PD-L1 detection by ICC in pleural effusions.

Conditions

  • Lung Neoplasms

Sponsors & Collaborators

  • Merck Sharp & Dohme LLC

    collaborator INDUSTRY

  • Heinrich-Heine University, Duesseldorf

    collaborator OTHER

  • Wissenschaftliches Institut Bethanien e.V

    lead OTHER

Principal Investigators

  • Winfried J Randerath, Prof. Dr. · Wissenschaftliches Institut Bethanien e.V

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2016-10-31
Primary Completion
2018-12-31
Completion
2018-12-31

Countries

  • Germany

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02855281 on ClinicalTrials.gov